Anastrozole plus fulvestrant vs. anastrozole alone for hormone receptor-positive advanced breast cancer: a meta-analysis of randomized controlled trials Meng LiYiting XiongWenxiong Zhang Review 01 February 2020 Pages: 269 - 278
Management of brain metastases in breast cancer: a review of current practices and emerging treatments Matthew N. MillsNicholas B. FiguraKamran A. Ahmed Review 06 February 2020 Pages: 279 - 300
Oncologic safety of immediate autologous fat grafting for reconstruction in breast-conserving surgery Camile Cesa StumpfÂngela Erguy ZucattoJorge Villanova Biazús Review 06 February 2020 Pages: 301 - 309
Increased number of intratumoral IL-17+ cells, a harbinger of the adverse prognosis of triple-negative breast cancer Xiao-Long QianPeng XuXiao-Jing Guo Preclinical study 29 January 2020 Pages: 311 - 319
Quantitative digital imaging analysis of HER2 immunohistochemistry predicts the response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma Aidan C. LiJing ZhaoAnil V. Parwani Preclinical Study 30 January 2020 Pages: 321 - 329
Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer Tomoko ShibayamaSiew-Kee LowShunji Takahashi Preclinical study 04 February 2020 Pages: 331 - 341
The role of Micro-CT in imaging breast cancer specimens Daniel DiCorpoAnkur TiwariJames Michaelson Preclinical study 04 February 2020 Pages: 343 - 357
GLL398, an oral selective estrogen receptor degrader (SERD), blocks tumor growth in xenograft breast cancer models Shanchun GuoChangde ZhangGuangdi Wang Preclinical study 06 February 2020 Pages: 359 - 368
Tertiary lymphoid structures and associated plasma cells play an important role in the biology of triple-negative breast cancers Dominique Yuan Bin SeowJoe Poh Sheng YeongJabed Iqbal Preclinical study 07 February 2020 Pages: 369 - 377
pHLIP(Var7)-P1AP suppresses tumor cell proliferation in MDA-MB-231 triple-negative breast cancer by targeting protease activated receptor 1 MingMing YuYueHua ChenXiaoDong Ding Preclinical study Open access 07 February 2020 Pages: 379 - 384
Inflammatory breast cancer cells are characterized by abrogated TGFβ1-dependent cell motility and SMAD3 activity Charlotte RypensMelike MarsanSteven J. Van Laere Preclinical Study 10 February 2020 Pages: 385 - 395
Three-dimensional microanatomy of human nipple visualized by X-ray dark-field computed tomography Naoki SunaguchiDaisuke ShimaoMasami Ando Preclinical study 13 February 2020 Pages: 397 - 405
Multiparametric radiomics methods for breast cancer tissue characterization using radiological imaging Vishwa S. ParekhMichael A. Jacobs Clinical trial Open access 04 February 2020 Pages: 407 - 421
Neoadjuvant therapy and sentinel lymph node biopsy in HER2-positive breast cancer patients: results from the PEONY trial Xiao SunXue-Er WangZhi-Min Shao Clinical Trial 07 February 2020 Pages: 423 - 428
Nomogram-based estimate of axillary nodal involvement in ACOSOG Z0011 (Alliance): validation and association with radiation protocol variations Matthew S. KatzLinda McCallArmando E. Giuliano Clinical trial 10 February 2020 Pages: 429 - 436
Associations between breast cancer subtype and neighborhood socioeconomic and racial composition among Black and White women Erin LinnenbringerArline T. GeronimusScarlett L. Gomez Epidemiology Open access 30 January 2020 Pages: 437 - 447
Accelerated aging in breast cancer survivors and its association with mortality and cancer recurrence Jingjing ZhuFei WangXiao-Ou Shu Epidemiology 04 February 2020 Pages: 449 - 459
The prognostic value of HER2 status and efficacy of anti-HER2 therapy in patients with HR-positive mucinous breast cancer: a nationwide study from the Korean Breast Cancer Society Hyung Suk KimTae Kyung YooByung Joo Chae Epidemiology 04 February 2020 Pages: 461 - 470
Male breast cancer: a closer look at patient and tumor characteristics and factors that affect survival using the National Cancer Database Samuel SarmientoMichael McCollMehran Habibi Epidemiology 10 February 2020 Pages: 471 - 479
Trends of female and male breast cancer incidence at the global, regional, and national levels, 1990–2017 Zhilin ChenLu XuPingming Fan Epidemiology 13 February 2020 Pages: 481 - 490
Trend and survival benefit of Oncotype DX use among female hormone receptor-positive breast cancer patients in 17 SEER registries, 2004–2015 Lu ZhangMei-Chin HsiehXiao-Cheng Wu Epidemiology 14 February 2020 Pages: 491 - 501
High risk of breast cancer in women with biallelic pathogenic variants in CHEK2 Irene RainvilleShanell HatcherSusan Manley Brief Report Open access 28 January 2020 Pages: 503 - 509
The implications of BRCA loss of heterozygosity (LOH) and deficient mismatch repair gene (dMMR) expression in the breast cancer of a patient with both inherited breast and ovarian cancer syndrome (BRCA2) and Lynch syndrome (MLH1) Steven SorscherKatherine AnsleyShakti Ramkissoon Brief Report 10 February 2020 Pages: 511 - 514
High serum levels of periostin are associated with a poor survival in breast cancer Tilman D. RachnerAndy GöbelAnn-Kathrin Bittner Brief Report 10 February 2020 Pages: 515 - 524
CYP24A1 polymorphisms and breast cancer risk Beuy JoobViroj Wiwanitkit Letter to the Editor 06 February 2020 Pages: 525 - 525